Pfizer Says Paxlovid Sales Fell 63% and Comirnaty Sales Fell 29% in Q3
Pfizer said Paxlovid sales slid 63% in the third quarter as Covid-19 infections declined in the U.S. and internationally; Comirnaty sales fell 29%.
Declining sales for Pfizer's Covid-19 products continue to weigh on the company's results. The drug and vaccine maker says sales of Paxlovid slid 63% in 3Q on lower Covid-19 infections across the U.S. and internationally, while Comirnaty sales fell 29%, driven in part by lower utilization in the U…